Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 6/2017

01.06.2017 | Nerve and Muscle (LH Weimer, Section Editor)

Update on Chemotherapy-Induced Peripheral Neuropathy

verfasst von: Comana Cioroiu, Louis H. Weimer

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this study was to briefly discuss chemotherapy-induced peripheral neuropathy (CIPN) and detail the most important and most recent chemotherapeutic agents implicated. This review will examine neuropathy mechanisms, risk factors, and clinical patterns; novel and prospective drugs with similar effects that are less well known to neurologists are discussed.

Recent Findings

CIPN is increasingly recognized for its clinical importance and effect on patient quality of life. Identification of risk factors is ongoing and may enable future risk stratification. Newer classes of agents and new members of existing classes are continually recognized, notably immune check point inhibitors, other monoclonal antibody treatments, novel immunomodulatory agents, and proteasome inhibitors. Advances regarding established classes including taxanes, platins, and vinca alkaloids are also reviewed.

Summary

CIPN is an important often dose-limiting toxicity. Multiple agents cause neuropathy; various clinical patterns are described. Future studies should aim at improved understanding of toxicity mechanisms and development of preventive and therapeutic strategies.
Literatur
1.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70.CrossRefPubMed
2.
• Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73(7):860–6. Good identification of importance of underappreciated CIPN manifestations. CrossRefPubMed
3.
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.CrossRefPubMed
4.
Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst. 2010;15(4):314–25.CrossRefPubMed
5.
Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767–74.CrossRefPubMed
6.
Bober BG, Shah SB. Paclitaxel alters sensory nerve biomechanical properties. J Biomech. 2015;48(13):3559–67.CrossRefPubMed
7.
Chiba T, Oka Y, Kambe T, Koizumi N, Abe K, Kawakami K, et al. Paclitaxel-induced peripheral neuropathy increases substance P release in rat spinal cord. Eur J Pharmacol. 2016;770:46–51.CrossRefPubMed
8.
Bobylev I, Joshi AR, Barham M, Ritter C, Neiss WF, Hoke A, et al. Paclitaxel inhibits mRNA transport in axons. Neurobiol Dis. 2015;82:321–31.CrossRefPubMed
9.
Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17(3):345–56.CrossRefPubMed
10.
Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015.
11.
Donehower RC, Rowinsky EK. An overview of experience with TAXOL (paclitaxel) in the U.S.A. Cancer Treat Rev. 1993;19(Suppl C):63–78.CrossRefPubMed
12.
Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, et al. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study. Support Care Cancer. 2016;24(4):1571–81.CrossRefPubMed
13.
Eckhoff L, Knoop A, Jensen MB, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292–300.CrossRefPubMed
14.
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, et al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther. 2016;9:5073–80.CrossRefPubMedPubMedCentral
15.
Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci. 2015;357(1–2):35–40.CrossRefPubMedPubMedCentral
16.
Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. 2015;21(22):5082–91.CrossRefPubMedPubMedCentral
17.
Apellaniz-Ruiz M, Lee MY, Sanchez-Barroso L, Gutierrez-Gutierrez G, Calvo I, Garcia-Estevez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res. 2015;21(2):322–8.CrossRefPubMed
18.
Beutler AS, Kulkarni AA, Kanwar R, Klein CJ, Therneau TM, Qin R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014;76(5):727–37.CrossRefPubMedPubMedCentral
19.
Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. Br J Clin Pharmacol. 2016;81(2):313–5.CrossRefPubMed
20.
Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol. 2000;424(4):563–76.CrossRefPubMed
21.
Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96(1):69–86.CrossRefPubMed
22.
Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969;19(4):367–74.CrossRefPubMed
23.
• Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996;77(7):1356–62. Classic initial description of this association. Many additional cases later reported. CrossRefPubMed
24.
Nakamura T, Hashiguchi A, Suzuki S, Uozumi K, Tokunaga S, Takashima H. Vincristine exacerbates asymptomatic Charcot-Marie-Tooth disease with a novel EGR2 mutation. Neurogenetics. 2012;13(1):77–82.CrossRefPubMed
25.
Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–23.CrossRefPubMedPubMedCentral
26.
Barzegar-Fallah A, Alimoradi H, Mehrzadi S, Barzegar-Fallah N, Zendedel A, Abbasi A, et al. The neuroprotective effect of tropisetron on vincristine-induced neurotoxicity. Neurotoxicology. 2014;41:1–8.CrossRefPubMed
27.
Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain. 2016;139(Pt 12):3092–108.CrossRefPubMed
28.
• Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116(5):3436–86. Comprehensive review of current and anticipated agents in this established class. CrossRefPubMedPubMedCentral
29.
de Carvalho Barbosa M, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, et al. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res. 2014;74(21):5955–62.CrossRefPubMedPubMedCentral
30.
Lucchetta M, Lonardi S, Bergamo F, Alberti P, Velasco R, Argyriou AA, et al. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol. 2012;70(6):899–902.CrossRefPubMed
31.
Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol. 2015;54(4):463–9.CrossRefPubMed
32.
Padman S, Lee J, Kumar R, Slee M, Hakendorf P, Richards A, et al. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)—cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer. 2015;23(3):861–9.CrossRefPubMed
33.
Makker PG, Duffy SS, Lees JG, Perera CJ, Tonkin RS, Butovsky O, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One. 2017;12(1):e0170814.CrossRefPubMedPubMedCentral
34.
Bobylev I, Joshi AR, Barham M, Neiss WF, Lehmann HC. Depletion of mitofusin-2 causes mitochondrial damage in cisplatin-induced neuropathy. Mol Neurobiol. 2017.
35.
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.
36.
Kelley MR, Wikel JH, Guo C, Pollok KE, Bailey BJ, Wireman R, et al. Identification and characterization of new chemical entities targeting apurinic/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther. 2016;359(2):300–9.CrossRefPubMed
37.
Zhu J, Carozzi VA, Reed N, Mi R, Marmiroli P, Cavaletti G, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Sci Rep. 2016;6:28861.CrossRefPubMedPubMedCentral
38.
Saifee TA, Elliott KJ, Rabin N, Yong KL, D'Sa S, Brandner S, et al. Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst. 2010;15(4):366–8.CrossRefPubMed
39.
Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan 3rd TH. Bortezomib-associated demyelinating neuropathy—clinical and pathologic features. J Clin Neuromuscul Dis. 2015;16(4):202–9.CrossRefPubMed
40.
Peng L, Ye X, Zhou Y, Zhang J, Zhao Q. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer. 2015;23(9):2813–24.CrossRefPubMed
41.
Hu B, Zhou Q, Wu T, Zhuang L, Yi L, Cao J, et al. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther. 2017.
42.
Liu H, Xu R, Huang H. Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma. Exp Ther Med. 2016;12(5):3041–6.PubMedPubMedCentral
43.
Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057–65.CrossRefPubMed
44.
Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guerin-Charbonnel C, Ferrer L, et al. A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in European patients with multiple myeloma. Clin Cancer Res. 2016;22(17):4350–5.CrossRefPubMed
45.
Ale A, Bruna J, Calls A, Karamita M, Haralambous S, Probert L, et al. Inhibition of the neuronal NFkappaB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology. 2016;55:58–64.CrossRefPubMed
46.
Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, et al. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer. 2016;24(7):3105–10.PubMed
47.
• Dalla Torre C, Zambello R, Cacciavillani M, Campagnolo M, Berno T, Salvalaggio A, et al. Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study. Neurology. 2016;87(11):1161–6. Prospective study of this agent using better neuropathy ascertainment methods. CrossRefPubMed
48.
Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497–503.CrossRefPubMedPubMedCentral
49.
Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA. Mechanism of action of ixabepilone and its interactions with the betaIII-tubulin isotype. Cancer Chemother Pharmacol. 2015;76(5):1013–24.CrossRefPubMed
50.
Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of betaIII-tubulin expression as a predictive marker. Oncologist. 2013;18(7):787–94.CrossRefPubMedPubMedCentral
51.
Ebenezer GJ, Carlson K, Donovan D, Cobham M, Chuang E, Moore A, et al. Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients. Ann Clin Transl Neurol. 2014;1(9):639–49.CrossRefPubMedPubMedCentral
52.
McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, et al. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;144(1):101–6.CrossRefPubMed
53.
Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, et al. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer. Lung Cancer. 2013;80(3):319–25.CrossRefPubMed
54.
Wozniak KM, Wu Y, Farah MH, Littlefield BA, Nomoto K, Slusher BS. Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy. Neurotox Res. 2013;24(3):338–44.CrossRefPubMedPubMedCentral
55.
Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, et al. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a phase II, single-arm, multicenter study. Breast Cancer (Dove Med Press). 2016;8:231–9.
56.
Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2012;11(2):101–11.CrossRefPubMed
57.
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010;28(31):4747–54.CrossRefPubMedPubMedCentral
58.
Beydoun SR, Shatzmiller RA. Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment. Clin Neurol Neurosurg. 2010;112(10):900–2.CrossRefPubMed
59.
Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-Gonzalez S, Prat A, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2016.
60.
• Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806–12. Informative review of various neurotoxicity forms associated with this relatively new class of agents. CrossRefPubMed
61.
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93.CrossRefPubMedPubMedCentral
62.
Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol. 2016;46(9):875–8.CrossRefPubMed
63.
Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307–8.CrossRefPubMed
64.
Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745.CrossRefPubMedPubMedCentral
65.
Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25.CrossRefPubMed
66.
Pastorelli F, Derenzini E, Plasmati R, Pellegrini C, Broccoli A, Casadei B, et al. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2013;54(10):2318–21.CrossRefPubMed
Metadaten
Titel
Update on Chemotherapy-Induced Peripheral Neuropathy
verfasst von
Comana Cioroiu
Louis H. Weimer
Publikationsdatum
01.06.2017
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 6/2017
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0757-7

Weitere Artikel der Ausgabe 6/2017

Current Neurology and Neuroscience Reports 6/2017 Zur Ausgabe

Epilepsy (CW Bazil, Section Editor)

The New Classification of Seizures by the International League Against Epilepsy 2017

Infection (J Halperin, Section Editor)

Neuroimaging in Central Nervous System Infections

Neuro-Oncology (L Abrey, Section Editor)

The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma–Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses

Neuroimaging (DJ Brooks, Section Editor)

Reward Prediction Errors in Drug Addiction and Parkinson’s Disease: from Neurophysiology to Neuroimaging

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise